Clinical trial

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

NCT04434482

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-08-07

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2020-08-07Date precision: day

Registry last updated2024-09-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Solid Tumoursunresolved

Small Cell Lung Cancerunresolved

Interventions

IMP4297(senaparib)DRUG

Sponsors & collaborators

Impact Therapeutics, Inc.lead sponsor

Mapped research locations

SeoulSouth Korea2 TainanTaiwan2 ColumbusOhio, United States1 TaipeiTaiwan1 BeijingChina1 ShanghaiChina1 TaichungTaiwan1 CantonOhio, United States1 TaoyuanTaiwan1 WuhanChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04434482 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.